Cargando…
Immune checkpoint inhibitor therapy-induced autoimmune polyendocrine syndrome type II and Crohn’s disease: A case report
BACKGROUND: The development of immune checkpoint inhibitors (ICIs) has heralded a new era in cancer treatment, enabling the possibility of long-term survival in patients with metastatic disease. Unfortunately, ICIs are increasingly implicated in the development of autoimmune diseases. CASE SUMMARY:...
Autores principales: | Gao, Mei-Juan, Xu, Yan, Wang, Wen-Bo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10237137/ https://www.ncbi.nlm.nih.gov/pubmed/37274046 http://dx.doi.org/10.12998/wjcc.v11.i14.3267 |
Ejemplares similares
-
Immune Checkpoint Blockade Anti–PD-L1 as a Trigger for Autoimmune Polyendocrine Syndrome
por: Lanzolla, Giulia, et al.
Publicado: (2019) -
Shock: A possible presenting manifestation of autoimmune polyendocrine syndrome type II
por: Banzal, Subodh, et al.
Publicado: (2014) -
Mixed phenotypic presentation of autoimmune polyendocrine syndrome type II in adolescent female
por: Kumar, Sandip, et al.
Publicado: (2020) -
Oral microbiota in autoimmune polyendocrine syndrome type 1
por: Bruserud, Øyvind, et al.
Publicado: (2018) -
Autoimmune Polyendocrine Syndromes in the Pediatric Age
por: Paparella, Roberto, et al.
Publicado: (2023)